Indometacin farnesil (INN) is a prodrug of the non-steroidal anti-inflammatory drug indometacin designed to reduce the occurrence of side-effects by esterification of the carboxyl group on indometacin with farnesol. Indometacin farnesil was first approved in Japan in 1991 and is available in Japan and Indonesia under the trade names Infree and Dialon respectively.
This page contains content from the copyrighted Wikipedia article "Indometacin farnesil"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
